Rationale and common goals
The objective of the program Cellular & Molecular Mechanisms is to find causal relationships in brain mechanisms of the healthy brain and the origin of disease. We investigate molecular processes and integrate such processes at higher levels of organization: organelles, cells, networks and the whole brain. In order to treat brain pathologies, it is necessary to improve the understanding of basic brain functions and assess which molecular and physiological mechanisms are involved in those functions. The strength of this theme is its uniform importance for all specific brain disease indications and its links to all other programs. Moreover it includes cutting edge technology and the experts that are needed to implement this.
Key indicators
- Mechanistic research.
- Aiming to elucidate cause and consequence in biological and pathological processes.
- Connecting genome to phenotype.
- Using quantitative as well as qualitative approaches.
Assets
- Top class scientists: top papers, 6 VICIs, 2ERCs, coordinators of large EU projects.
- Cutting edge technology and infrastructure: quantitative proteomics, life cell imaging, FACS, laser capture dissection, brain organoid culture, In utero electroporation, in vivo multi-unit recordings and optogenetics, cellomics, computational modeling.
- Excellent integration of expertise into joint multidisciplinary projects.
- Availability of essential animal models systems.
Translational links
Cellular and Molecular Mechanisms is capable of nurturing all clinical themes in Amsterdam Neuroscience while also maintaining good connections to industry (biotech, pharma), including spin-offs (Sylics BV and Macrobian BV) and also is able to stimulate new initiatives due to its strong scientific and innovative nature.
Making the difference
The essence of this research program is:
- The high quality-driven research with strong team spirit and availability of involved experts on all topics.
- The ability to bridge the gap between genome information and neurobiological processes and behavioral phenotypes.
- The use of cutting edge technology and availability of unique animal models to solve complex questions.
- The implementation of human embryonic stem cell - and patient derived induced pluripotent stem cell (iPSC) strategies in order to generate new models that connect fundamental brain research towards clinical relevant questions.
Program leaders
Taskforce team
Program members
-
Adlin Abramian
-
Aline Mak
-
Amélie FréalDR.
-
Amparo Roig Adam
-
Ana Carreras Mascaro
-
Angela Getz
-
Anna Galakhova
-
Bastian Meth
-
Bernardo de Azevedo Pinto Castro Maciel
-
Biswajit Moharana
-
Carlos Fitzsimonsdr.
-
Christiaan Levelt
-
Christian A. Lohmann
-
Cyriel Pennartzprof. dr.
-
Daniele Avitabile
-
Debora Pita Illobre
-
Djai Heyer
-
Eline Mertens
-
Fiona Murphy
-
Frank Koopmans
-
Galia Polyak
-
GEM Abbink
-
Guus Smit
-
Huib Mansvelder
-
Ilma Revers
-
Jan van WeeringPI PhD
-
Janina Kupke
-
Jasper Smits
-
Jean Pie
-
Jean Pie
-
Jian Dong
-
Johana Jarkulischová
-
Josse Poppinga
-
Joyce Reesen
-
Julien Fiorilli
-
Juliette Chevalier
-
Juraj Ondris
-
Ka Wan Li
-
Kim Verdaasdonk
-
Lara Janssen
-
Lars van der Heidedr.
-
Léa Dugue
-
Lianne Klaver
-
Lotte Razenberg
-
Marcel Oberlaender
-
Marco Hoekmandr.
-
Margo van der KnaapPI PROF.DR.
-
Marieke Meijerdr. DR.
-
Mark Verheijen
-
Marta Jorge Oliva
-
Marten Smidtprof. dr.
-
Martijn van den HeuvelPI DR.
-
Matthew Vanheusden
-
Matthijs VerhagePI PROF.DR.
-
Maureen van der Grinten
-
Maxime Malivert
-
Miranda Moore
-
Natalia Goriounova
-
Natia Shamugia
-
Nico Peter van Til
-
Noortje van Geest
-
Panthea Nemat
-
Pieter RoelfsemaPI Prof. PhD
-
Priyanka Rao
-
Puk Nuijten
-
Quinty Bisseling
-
René Wilbers
-
Renee Pullen
-
Robin Weiler
-
Roel de Haan
-
Romina Ambrosini Defendi
-
Ruud Toonen
-
Sabine Spijker
-
Salma Ramon Carrasco
-
Siemon de Lange
-
Stan Driessens
-
Sven Kerst
-
Sylvia Korhorn
-
Theresa Priebe
-
Thomas Blok
-
Tim Heistek
-
Tjerk Swinkels
-
Tom Coopmans
-
Torben van Voorst
-
Vanessa Simoes Lourenco
-
Vasiliki Theodorou
-
Vivienne Aline Bauer
-
Wessel van WieringenDR.